GPCR-Symposium 2016

1st Symposium on Functional Autoantibodies Targeting G-Protein-Coupled Receptors

Lübeck, October 07-09, 2016

Greeting from the symposium chair

It is a great pleasure to announce the first symposium on functional autoantibodies targeting G-protein-coupled receptors (GPCRs) in Lübeck. GPCRs are involved in a variety of physiological and pathophysiological processes. So far, much effort has been made on anti-GPCR drug discovery with a focus on the development of small molecules and monoclonal antibodies for the treatment of cancer, infection, metabolic disorders or inflammatory diseases. Recently, functional autoantibodies against GPCRs were identified in various diseases associated with pathogenesis, uncovering a potential new field of therapeutic intervention. Thus, the aim of this symposium is to combine the current knowledge about the role of GPCRs in different pathologies, their mode of action and state-of-the-art research techniques to identify common fundamental pathways that can be transferred to other disease entities with similar manifestations.

Prof. Dr. Gabriela Riemekasten
- Director, Department of Rheumatology -

15:00 p.m.	Registration
17:00 p.m.	Welcome from the University President: Hendrik Lehnert Welcome the chair of the Symposium: Gabriela Riemekasten
17:20 p.m.	Opening Lecture: Autoantibodies against GPCR – a new principle to understand diseases

09:00 a.m.	GPCRs and their modulation in neurological diseases Madlen Löbel: Immunoadsorption to remove ß adrenergic and M acetylcholine receptor antibodies in Chronic Fatigue Syndrome Lasse Melvaer Giil: Antibodies to signaling molecules and receptors in Alzheimer’s disease - Immune-related cognitive dysfunction and mortality. Oral presentations from selected abstracts
10:30 a.m.	GPCRs and their modulation in cardiovascular diseases Florian Herse: AT1-Autoantibodies in hypertensive disease of pregnancy Fritz Boege: Agonistic autoan Annekathrin Haberland: BC 007, an aptamer for the neutralization of functional autoantibodies directed against GPCR that are identified by a functional test Oral presentations from selected abstracts
13:15 p.m.	Poster Session
14:00 p.m.	GPCRs and their modulation in hemato-oncological diseases Thomas Luft: Role of autoantibodies directed against GPCRs in GVHD after allogenic SCT Frank Gieseler: PAR2, a G-protein coupled receptor protein (GPR11): Possible relevance of aberrant expression by tumor cells Oral presentations from selected abstracts
15: 30 p.m.	GPCRs and their modulation in rheumatic diseases Gabriela Riemekasten: Antibodies against GPCR in systemic sclerosis Xinhua Yu: Autoantibodies against peptides of GPCRs in primary Sjögren’s syndrome Otávio Cabral-Marques: Physiological IgG autoantibodies regulate a network of G protein coupled receptors and growth factors Oral presentations from selected abstracts

09:00 a.m.

GPCR antibodies and their signaling

Duska Dragun: Personalized medicine for transplant recipients according to anti-GPCR antibody status

Aurélie Philippe: New approaches to study functional selectivity in GPCR signaling
Christian Sadik: SSc- IgG effects are mediated through distinct pathways in THP-1 cells

Oral presentations from selected abstracts

11:00 a.m.

Therapeutic approaches regarding GPCR modulation

Roland Jahns: Novel therapeutic approaches in cardiac autoimmunity:
Blocking peptides against beta1-adrenoceptor autoantibodies

Manuela Camino: Autoantibodies against beta 1 adrenergic receptors in dilated cardiomiopathy in children - treatment with immunoadsorption

Oral presentations from selected abstracts

12:00 a.m.

Panel discussion and closing remarks: Gabriela Riemekasten Future directions and therapeutic approaches